Alzheimer's Disease
Advancing Alzheimer's Disease Clinical Trials
We have focused on Alzheimer's disease studies since 2006. Today, we are a leading neuroimaging provider at the forefront of advancing Alzheimer's drug trials. Our solutions bring together deep therapeutic expertise, breakthrough AI analytics and operational agility to deliver extraordinary clinical insights.
In international EPAD and AMYPAD consortia projects, our data analysis algorithms have quantitatively analyzed brain scans to extract as much information as possible, increasing the chances of detecting therapy-induced changes in AD clinical trials.
Our AI-powered data analytics combine imaging with other patient data – such as that gathered from wearable biosensors – allowing us to predict the rate of Alzheimer’s disease progression in individual patients. Using this approach, we can also identify patients who would benefit from enrollment in Alzheimer’s research studies.
Unique technologies
- We support all phases of Alzheimer’s clinical trials from early to late phase studies. Our imaging and AI technologies are easily scalable for late phase, multi-site trials requiring management and analysis of multiple, large data sets.
- Our technology improves data quality and consistency in global multi-centre trials by standardising imaging, wearables and site set-up.
Connected networks
- Our network consists of over 2,000 qualified imaging centers with established connections to clinical research sites.
- We are truly patient-centric, combining insight into people living with Alzheimer’s disease with training and technology to improve recruitment, retention and support for Alzheimer’s disease study participants.
Expert neuroradiology
- Our team of expert neuroradiologists perform centralized, real-time, standardized safety reads.
- Our solutions ensure accuracy through intra- and inter-reader variability testing.
- We offer flexible read paradigms, whether single central over-reads or double adjudicated reads.
Collaborations
- We collaborate with international scientific consortia, academic institutions and global networks of research sites.
- Our collaborations are an integral part of our proven track record in translating novel biomarkers into successful neuroimaging solutions in AD clinical trials.
Optimization of Tau PET Imaging for Alzheimer’s Clinical Development
To find out more about the use of Tau PET tracers in AD clinical trials and how we support Alzheimer's studies with advanced Tau PET operational and analytical methodologies, watch our webinar. We address the role of Tau in disease progression, look at key factors in Tau PET imaging and analysis in CNS clinical trials and compare the various Tau PET tracers available.
We offer comprehensive neuroimaging solutions to support with patient eligibility, stratification, drug safety and efficacy in Alzheimer's clinical trials.
About Alzheimer's Disease
Alzheimer's disease affects 50 million people worldwide
Alzheimer’s disease (also referred to as AD) affects around 50 million people worldwide and has a devastating physical, emotional and financial impact to patients and families. With a 99.6% failure rate of Alzheimer's clinical trials, there are currently no available therapies to address the underlying disease pathology.
Biopharmaceutical sponsors are addressing this with innovations in Alzheimer's drug trials including diversifying targets, increasing use of biomarkers to define trial populations and expanding assessment into milder stages of AD for outcome measures.
In this evolving landscape of Alzheimer’s research studies, Neuroimaging is more important than ever as it allows us to visualize extraordinary information about the structural, functional and biochemical characteristics of the human brain. Today, sponsors require highly advanced medical imaging in order to navigate the complexities involved in Alzheimer’s drug development.